Membrane cofactor protein (MCP, CD46) is a complement protein that protects organs from injury by complement

Membrane cofactor protein (MCP, CD46) is a complement protein that protects organs from injury by complement. with locus heterogeneity. == Conclusions == Thorough clinical characterisation of patients can assist in prioritising which genes should be tested. The clinician-driven customised comprehensive genetic support has worked effectively for New Zealand. Next generation sequencing will play an increasing role in disorders with locus heterogeneity. Keywords: Primary immunodeficiencies, Genetic testing, Next generation sequencing == Background == Failure to effectively fight infections is a hallmark of immunodeficiencies (IDs) such as primary immunodeficiency disorders (PIDs) where rare genetic Dimethyl trisulfide defects lead to compromised sponsor defences. Affected patients are prone to recurrent and severe infections [1]. Some patients develop autoimmunity and malignancy because of immune dysregulation [2, 3]. The severity of these disorders ranges from asymptomatic IgA deficiency to life threatening conditions such as severe combined immunodeficiency (SCID). Nearly all PIDs are monogenic disorders. Almost 300 genetic defects have so far been recognized [4]. A delayed diagnosis can impact on prognosis if a patient has a life threatening disorder, such as presymptomatic males with X-linked lymphoproliferative syndrome (XLP) from SH2D1A or BIRC4 mutations [5]. New Zealand is a developed Dimethyl trisulfide geographically isolated country with a population of 4. 4 million in the South Pacific. A dedicated comprehensive customised genetic testing support for PIDs was established in 2005 [6]. Dimethyl trisulfide The primary aim of the service was to offer rapid genetic testing for any PID disorder with a published sequence. The support initially offered genetic testing for XLP and X-linked agammaglobulinemia (XLA). Over time, the scope from the service offers broadened to include patients with other PIDs as well as haemophagocytic lymphohistiocytosis (HLH) and atypical haemolytic uremic syndrome (aHUS) and periodic fever/autoinflammatory syndromes. HLH is a rare but potentially fatal disease of uncontrolled immune activation. Genetic testing for HLH overlaps with testing intended for XLP. Similarly, genetic testing plays an important role in patients with aHUS. Identification of the specific genetic defect impacts on clinical management Dimethyl trisulfide of aHUS patients. Membrane cofactor protein (MCP, CD46) is a complement protein that protects organs from injury by complement. Mutations in MCP are associated with aHUS [7]. Patients with terminal renal failure can undergo successful renal transplantation if they only have an MCP mutation [8]. The transplanted kidney expresses normal levels of MCP and is protected against complement mediated damage. In contrast mutations of factor H and I could damage a transplanted kidney, hence the importance of undertaking genetic studies in patients with aHUS. This is particularly important given that eculizumab is not funded in New Zealand. The service provides testing intended for periodic fever syndromes. This group of disorders include cryopyrin-associated periodic syndrome (CAPS), tumor necrosis element receptor associated periodic syndrome (TRAPS), familial Mediterranean fever (FMF) and mevalonate kinase deficiency (MKD). Rabbit Polyclonal to OR8S1 Identification from the exact genetic defect in these autoinflammatory disorders is very important as the treatments vary. Tertiary hospitals offering PID testing services in developed and developing countries have reported a wide spectrum of PIDs within their respective communities [912]. Access to specialised clinical and laboratory resources differ among the countries, depending on the expertise and financial resources of each healthcare system [13]. We have made the case for a national clinical support for PIDs in New Zealand [14]. It is hoped the customised genetic testing support will be integrated into a future national PID support. In this report, we review the results of patients referred to the LabPlus comprehensive customised genetic testing support between 2005 and 2014. We also discuss the implications of future genetic testing with the advent of next generation sequencing (NGS). == Methods == The customised genetic testing support is clinician-driven and a test is rapidly developed if there is an appropriate clinical ask for. The support typically offers results within a week intended for smaller genes and up to three weeks for longer genes. In addition to the rapid turnaround time, it has also reduced the need to send samples to overseas laboratories. For most from the genes tested, it has been much cheaper to undertake mutation analysis in New Zealand, compared with overseas laboratories. Twice weekly meetings are kept to discuss cases and to review the results of other tests including protein-based assays and flow cytometry. The genetic testing strategy is based on detailed clinical and phenotypic data. The service follows the guidelines intended for molecular diagnostic laboratories issued by.